%PDF-1.4
%
49 0 obj
<>
endobj
46 0 obj
<>
endobj
127 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-09-08T17:55:55Z
2024-03-28T01:36:18-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T01:36:18-07:00
application/pdf
Heather
2002-913.oct
uuid:b7c8d617-1dd1-11b2-0a00-580827edca00
uuid:b7c8d61b-1dd1-11b2-0a00-380000000000
endstream
endobj
35 0 obj
<>
endobj
36 0 obj
<>
endobj
50 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 21 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 23 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 25 0 R/Type/Page>>
endobj
7 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 27 0 R/Type/Page>>
endobj
10 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 29 0 R/Type/Page>>
endobj
147 0 obj
[152 0 R]
endobj
148 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
/GS1 gs
420 777 137 -27 re
f*
0 0 0 1 K
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:10)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2164)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.04781 Tw 10 0 0 10 54 713.1616 Tm
(protect against the development of ischemic manifestations)Tj
0.01311 Tw 0 -1.2 TD
[(in GCA. )55 (A)-208 (strong angiogenic activity in serum was recently)]TJ
0.0773 Tw T*
(associated with a reduced prevalence of ischemic manifes-)Tj
0.00349 Tw T*
(tations in GCA)Tj
0 Tc 0 Tw 6.5 0 0 6.5 114.6191 680.4615 Tm
(17)Tj
0.0034 Tw 10 0 0 10 121.1191 677.1616 Tm
[(. )18 (W)80 (e found no dif)18 (ference in the frequencies)]TJ
-0.00011 Tc 0.0374 Tw -6.7119 -1.2 Td
[(of )18 (VEGF polymorphisms studied in GCA)-233 (patients with and)]TJ
0.2093 Tw T*
(those without ischemic manifestations, although some of)Tj
0.3282 Tw T*
[(these polymorphisms are associated with higher )18 (VEGF)]TJ
0 Tw T*
(production.)Tj
0.08681 Tw 1.2 -1.2 Td
(Our data indicate that carriers of C634 and I alleles are)Tj
0.08279 Tw -1.2 -1.2 Td
[(associated with susceptibility to developing GCA. )18 (These 2)]TJ
0.0079 Tc 0.367 Tw T*
[(polymorphisms may be associated with higher )18 (VEGF)]TJ
-0.00011 Tc 0.1786 Tw T*
[(production. No significant dif)18 (ference in these alleles was)]TJ
0.25751 Tw T*
[(found in GCA)-453 (patients with compared to those without)]TJ
0.1067 Tw T*
[(ischemic manifestations. )18 (VEGF plays an important role in)]TJ
0.02451 Tw T*
[(the GCA)-220 (inflammatory response, and genetically controlled)]TJ
0.0782 Tw T*
[(variation in )18 (VEGF production may influence susceptibility)]TJ
0.02499 Tw T*
(to this condition.)Tj
/T1_2 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61 487.1616 Tm
[(1.)-875 (W)80 (eyand CM, Goronzy JJ. Pathogenic principles in giant cell)]TJ
1.675 -1.25 Td
(arteritis. Int J Cardiol 2000;75 Suppl 1:S9-S15.)Tj
-1.675 -1.25 Td
[(2.)-875 (W)80 (eyand CM, Goronzy JJ. )18 (The Dunlop-Dottridge Lecture: )18 (The)]TJ
1.675 -1.25 Td
(pathogenesis of giant cell arteritis. J Rheumatol 2000;27:517-22.)Tj
-1.675 -1.25 Td
[(3.)-875 (W)80 (eyand CM, Goronzy JJ. )55 (Arterial wall injury in giant cell arteritis.)]TJ
1.675 -1.25 Td
(Arthritis Rheum 1999;42:844-53.)Tj
-1.675 -1.25 Td
[(4.)-875 (W)80 (eyand CM, Goronzy JJ. Pathogenesis of giant cell arteritis. In:)]TJ
1.675 -1.25 Td
[(Hof)18 (fman GS, )18 (W)80 (eyand CM, editors. Inflammatory diseases of blood)]TJ
0 -1.25 TD
[(vessels. New )37 (Y)100 (ork: Marcel Dekker; 2002:413-24.)]TJ
0 Tc -1.675 -1.25 Td
[(5.)-875 (Kaiser M, )37 (Y)100 (ounge B, Bjornsson J, Goronzy JJ, )18 (W)80 (eyand CM.)]TJ
-0.00011 Tc 1.675 -1.25 Td
(Formation of new vasa vasorum in vasculitis. Production of )Tj
T*
[(angiogenic cytokines by multinucleated giant cells. )55 (Am J Pathol)]TJ
0 Tc 0 Tw T*
(1999;155:765-74.)Tj
-0.00011 Tc 0.00729 Tw -1.675 -1.25 Td
[(6.)-875 (Marumo T)74 (, )-18 (Schini-Kerth VB, )-18 (Busse )-18 (R. V)111 (ascular )-18 (endothelial )-18 (growth)]TJ
0.02499 Tw 1.675 -1.25 Td
[(factor activates nuclear factor)20 (-kappa B and induces monocyte)]TJ
T*
(chemoattractant protein-1 in bovine retinal endothelial cells.)Tj
T*
[(Diabetes 1999;48:1)37 (131-7.)]TJ
-1.675 -1.25 Td
[(7.)-875 (Kim I, Moon SO, Kim SH, Kim HJ, Koh )37 (YS, Koh GY)129 (. )18 (V)111 (ascular)]TJ
1.675 -1.25 Td
(endothelial growth factor expression of intercellular adhesion )Tj
T*
(molecule 1 \(ICAM-1\), vascular cell adhesion molecule 1 )Tj
T*
[(\(VCAM-1\), and E-selectin through nuclear factor)20 (-kappa B )]TJ
T*
(activation in endothelial cells. J Biol Chem 2001;276:7614-20.)Tj
-1.675 -1.25 Td
[(8.)-875 (Cid MC, Cebrian M, Font C, et al. Cell adhesion molecules in the)]TJ
1.675 -1.25 Td
(development of inflammatory infiltrates in giant cell arteritis:)Tj
33 57.171 Td
(inflammation-induced angiogenesis as the preferential site of )Tj
T*
[(leukocyte-endothelial cell interactions. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;43:184-94.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875 (Meliconi R, Pulsatelli L, Dolzani P)111 (, et al. )18 (V)111 (ascular endothelial)]TJ
1.675 -1.25 Td
[(growth factor production in polymyalgia rheumatica. )55 (Arthritis)]TJ
0 Tc T*
(Rheum 2000;43:2472-80.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875 (W)80 (atson CJ, )18 (W)80 (ebb NJA, Bottomley MJ, Brenchley PEC. Peripheral)]TJ
2.175 -1.25 Td
[(mononuclear cells express )18 (VEGF and the )18 (VEGF receptor FL)92 (T)92 (-1)]TJ
T*
[([abstract]. J )55 (Am Soc Nephrol 1996;7:1725.)]TJ
-2.1381 -1.25 Td
[(1)37 (1.)-875 (Renner )18 (W)92 (, Kotschan S, Hof)18 (fmann C, Obermayer)20 (-Pietsch B, Pilger)]TJ
2.1381 -1.25 Td
[(E. )55 (A)-220 (common 936 C/T)-257 (mutation in the gene for vascular endothelial)]TJ
T*
(growth factor is associated with vascular endothelial growth factor)Tj
T*
[(plasma levels. J )18 (V)111 (asc Res 2000;37:443-8.)]TJ
-2.175 -1.25 Td
[(12.)-875 (W)80 (atson CJ, )18 (W)80 (ebb NJ, Bottomley MJ, Brenchley PE. Identification)]TJ
2.175 -1.25 Td
(of polymorphisms within the vascular endothelial growth factor)Tj
T*
[(\(VEGF\) gene: correlation with variation in )18 (VEGF protein )]TJ
0 Tc T*
(production. Cytokine 2000;12:1232-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(13.)-875 (Brogan IJ, Khan N, Isaac K, Hutchinson JA, Pravica )18 (V)129 (, Hutchinson)]TJ
2.175 -1.25 Td
[(IV)129 (. Novel polymorphisms in the promoter and 5\325)-201 (UTR regions of)]TJ
T*
(the human vascular endothelial growth factor gene. Hum Immunol)Tj
0 Tc 0 Tw T*
(1999;60:1245-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875 (Haworth S, Ridgeway J, Stewart I, Dyer P)92 (A, Pepper L, Ollier )18 (W)92 (.)]TJ
2.175 -1.25 Td
(Polymyalgia rheumatica is associated with both HLA-DRB1*0401)Tj
0 Tc T*
(and DRB1*0404. Br J Rheumatol 1996;35:632-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(15.)-875 (W)80 (eyand CM, Hunder NN, Hicok KC, Hunder GG, Goronzy JJ.)]TJ
2.175 -1.25 Td
(HLA-DRB1 alleles in polymyalgia rheumatica, giant cell arteritis,)Tj
T*
[(and rheumatoid arthritis. )55 (Arthritis Rheum 1994;37:514-20.)]TJ
-2.175 -1.25 Td
[(16.)-875 (Salvarani C, Casali B, Boiardi L, et al. Intercellular adhesion )]TJ
2.175 -1.25 Td
(molecule 1 gene polymorphisms in polymyalgia rheumatica/giant)Tj
T*
[(cell arteritis: association with disease risk and severity)65 (. J Rheumatol)]TJ
0 Tc 0 Tw T*
(2000;27:1215-21.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875 (Cid MC, Hernandez-Rodriguez J, Esteban MJ, et al. )18 (T)35 (issue and)]TJ
2.175 -1.25 Td
(serum angiogenic activity is associated with low prevalence of)Tj
T*
(ischemic complications in patients with giant-cell arteritis.)Tj
T*
(Circulation 2002;106:1664-71.)Tj
-2.175 -1.25 Td
[(18.)-875 (A)92 (wata )18 (T)74 (, Inoue K, Kurihara S, et al. )55 (A)-220 (common polymorphism in)]TJ
2.175 -1.25 Td
[(the 5\325-untranslated region of the )18 (VEGF gene is associated with)]TJ
T*
(diabetic retinopathy in type 2 diabetes. Diabetes 2002;51:1635-9.)Tj
-2.175 -1.25 Td
[(19.)-875 (Y)111 (uuki )18 (T)74 (, Kanda )18 (T)74 (, Kimura )37 (Y)129 (, et al. Inflammatory cytokines in)]TJ
2.175 -1.25 Td
[(vitreous fluid and serum of patients with diabetic vitreoretinopathy)65 (.)]TJ
T*
(J Diabetes Complications 2001;15:257-9.)Tj
-2.175 -1.25 Td
[(20.)-875 (Shahbazi M, Fryer )55 (AA, Pravica )18 (V)129 (, et al. )18 (V)111 (ascular endothelial)]TJ
2.175 -1.25 Td
(growth factor gene polymorphisms are associated with acute renal)Tj
T*
[(allograft rejection. J )55 (Am Soc Nephrol 2002;13:260-4.)]TJ
ET
0 0 0 0 k
408 770 150 -25 re
f*
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
ET
/GS2 gs
BT
/T1_3 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
29 0 obj
<>stream
8;Z\7!H,gu%.jK`R.!^IM;trlPWMVfD+)ii4f(ni9OMHomK8!5I4i;:NmII9rc=_O
/Z8R2A$q7+Y^TsOAV34\fD5i7mS*)MYq+b)kd<6P-o:mOLd0c5Poo[%+t-K71)eTH1m@A9%:Tf`Ii&YoRpkZ&u`X:\+f?sXu[SGOVgPbb7M$ASd^Yr;Y
el"nb(Z1is)'75H7De&SX889fn62oo#1ZsjF%?*[ReboPkp3gPeeX[sDt2,`Sp/hd
mB]F_2']t+J;r`DPBCO%#?l,aL`s8aR9jm?R$OQHfk"!D>UQ6@
QUkKY>`"D]38U'0C*KR=-*JQR"W0uH=luYZ;bWO40Mf5UD[1!s[^=KV[!>41(H5'E
O(sb%0V)@jQ*.'RVcp3@YDd,4Nn);&hN$uecA>=6?PF?'be68mdMa:%W0eL*!/"h%
Ugep_Ehm"nQr!3b+Rd\+p?E5a#?j0-^)>l0;DkN*GQ8Lc9[\EWif5$@G3mlO[fZ0+
"D!%mMVVOG?QeBYM]MEZ1B
endstream
endobj
33 0 obj
[/Indexed/DeviceRGB 255 32 0 R]
endobj
32 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
58 0 obj
<>
endobj
62 0 obj
<>
endobj
13 0 obj
<>
endobj
88 0 obj
<>
endobj
133 0 obj
<>
endobj
15 0 obj
<>
endobj
16 0 obj
<>stream
HLPw9v_LEY=I1s_U!QS%#\ǏÂ6*A(,֨IԐ)`tbR5cZk
Iތݕ3;|.I$IFIXhnqE8mil$yeNI:%?礱'U[svaMﳭgMrPF&oVy
߃Rz2 rSIFۊfp1VhxƲ;JhK#. oYf__UIqba?09
M@ 2XXl4sHDL6*pdp
{HFHjV4nzߨO@FQ%v-1_ZpOcn͗
Q
J֢ۢk<Ԡfl̍ՅA:0
E|j8/wZ/[0ZgրCOEJ(>?0B5֔wDzyj<3ܟ@RWƯr*d֏!ZɐNQ+ѕshw^%||4q>0'~9ZMɫ5U%I(woa',lގ2»HZ"RA2-64k
ԆS":Z7GBH?A,SD@Ac*o}<^d|im蛞D4x<)Kݷ~7ǔui?%hɐKVDzofF"yM[klЉZ!ʎl ޢhP`eifo"5euwfuTHtrSIV^@[^